Insulin and women: particular features and risks
Insulin is the hormone that lets the body use glucose for energy, and as a medicine it is indispensable and life-saving for people with diabetes. For women, insulin interacts with the reproductive hormones in ways that create particular features across the menstrual cycle, pregnancy and menopause. This article, from the editorial team, explains those sex-specific aspects and states plainly why insulin must never be used outside medical care — a misuse that can kill.
What insulin does
Insulin is produced by the beta cells of the pancreas and acts as the body's main signal to lower blood glucose. After a meal, it allows muscle and fat cells to absorb glucose and prompts the liver to store it, keeping blood sugar within a narrow, safe range. Without enough insulin, or without a proper response to it, glucose rises and the metabolism is thrown into disorder.
Diabetes comes in forms that reflect different failures of this system. In type 1 diabetes the pancreas makes little or no insulin, so injected insulin is essential for survival. In type 2 diabetes the body becomes resistant to insulin's effect, and treatment may eventually include insulin alongside other approaches.
As a treatment, insulin is remarkably effective but unforgiving. Too little leaves glucose dangerously high; too much drives it dangerously low, a state called hypoglycaemia that can cause confusion, seizures, coma and death. This narrow margin is the backdrop to everything that follows.
Insulin also does more than manage sugar. It influences fat storage, protein handling and growth signalling, which is why it intersects with so many other systems — including, as we will see, the female reproductive hormones.
Insulin across the menstrual cycle
One feature specific to women is that insulin sensitivity shifts across the menstrual cycle. The hormones oestrogen and progesterone, which rise and fall through the month, influence how responsive tissues are to insulin. In the second half of the cycle, when progesterone is high, many women become somewhat more insulin resistant, meaning the same amount of insulin has a slightly weaker effect.
For women with diabetes, this can translate into noticeable patterns: blood glucose may run a little higher in the days before a period and then settle afterwards. Clinicians and patients who recognise this can anticipate it, and management is adjusted by the medical team rather than guessed at.
These fluctuations are usually modest but real, and they illustrate a broader truth: female physiology adds a layer of variability that men do not experience in the same way. It is one reason diabetes care is individualised and why self-adjustment without guidance is risky.
The interaction also runs the other way. Insulin resistance is central to polycystic ovary syndrome, a common condition in which high insulin levels disturb ovarian hormone production, affecting cycles and fertility — a reminder of how tightly metabolic and reproductive hormones are linked.
Pregnancy and gestational diabetes
Pregnancy transforms a woman's relationship with insulin. As the placenta grows, it produces hormones that deliberately increase insulin resistance, ensuring more glucose is available to the developing baby. A healthy pancreas compensates by making more insulin; when it cannot keep up, gestational diabetes develops.
| Stage | Insulin picture | Clinical relevance |
|---|---|---|
| Early pregnancy | Sensitivity may rise | Risk of lows in women with type 1 diabetes |
| Later pregnancy | Resistance increases | Insulin needs often rise substantially |
| Gestational diabetes | Pancreas cannot meet demand | Managed by diet and, if needed, insulin |
| After delivery | Resistance falls quickly | Doses recalculated to avoid lows |
Insulin is the preferred treatment when gestational diabetes needs medication, because it does not cross the placenta in a way that harms the baby. Women with pre-existing diabetes often find their insulin requirements change dramatically through pregnancy, demanding close specialist supervision.
The stakes are high for both mother and child, and management is a team effort involving obstetricians and diabetes specialists. This is a clear example of why insulin dosing is a clinical matter calibrated to a changing body, not a fixed recipe.
After birth, insulin needs typically drop sharply, and doses must be recalculated promptly to avoid dangerous lows — another moment where medical oversight is essential.
Menopause and longer-term considerations
As women approach and pass menopause, falling oestrogen tends to increase insulin resistance and shift fat distribution, which can raise the risk of type 2 diabetes. Weight changes, altered sleep and reduced activity around this time compound the effect. For women already living with diabetes, control may become harder and treatment may need adjusting.
These transitions highlight that a woman's insulin needs are not static but evolve across decades. Good diabetes care tracks these shifts and adapts, which is why regular review with a clinical team matters so much.
Lifestyle remains central throughout. Physical activity improves insulin sensitivity at every stage, and a balanced diet helps smooth the glucose swings that hormonal changes can bring. These general measures are safe to pursue and benefit metabolic health broadly.
None of this, however, changes the fundamental rule that the medicine itself is handled under supervision. The female-specific features make the case for individualised care stronger, not for experimentation.
The grave danger of non-medical use
It must be stated in the strongest terms: insulin used by anyone who does not medically need it, or in doses not set by a doctor, is extremely dangerous and can be fatal. Insulin has sometimes been misused in body-building circles for its effects on nutrient uptake. This is a practice that has killed people, and this article will not describe any protocol.
The reason is simple and brutal. Injecting insulin without matching it to food and glucose levels drives blood sugar down, and severe hypoglycaemia can cause seizures, brain damage, coma and death within a short time. Unlike many drugs, the margin between an effect and a catastrophe is razor-thin, and the consequences can arrive fast, including during sleep when no one can intervene.
- Hypoglycaemia from excess insulin can be rapid, severe and lethal.
- There is no safe self-dosing without glucose monitoring and clinical training.
- The danger is greatest at night, when a low may go unnoticed.
- Products from unregulated sources add further, unpredictable risk.
For women specifically, the cyclical changes in insulin sensitivity described above make the response even less predictable, compounding an already deadly hazard. There is no version of non-medical insulin use that is sensible or safe.
If you have diabetes, work closely with your care team; if you do not, insulin has no legitimate role in your life. Readers may also find our articles on how blood glucose is regulated, on PCOS and insulin resistance, and on safe approaches to body composition useful background.
Conclusions of the editorial team
Insulin is a life-saving medicine with features specific to women: its effect shifts across the menstrual cycle, rises in demand through pregnancy, and tends to weaken around menopause. These patterns make individualised, supervised care essential.
Understanding them helps women with diabetes and their clinicians anticipate change rather than be caught out by it, and underlines how closely metabolic and reproductive hormones are intertwined.
Above all, insulin must never be used outside genuine medical need and professional guidance. Misuse causes severe hypoglycaemia that can kill. For diabetes, partner with your care team; otherwise, insulin has no place at all.
References
- American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2023;46(Suppl 1).
- Yki-Jarvinen H. Sex and insulin sensitivity. Metabolism. 1984;33(11):1011-1015.
- Catalano PM. Trying to understand gestational diabetes. Diabet Med. 2014;31(3):273-281.
- Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited. Endocr Rev. 2012;33(6):981-1030.
- Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. Physiol Behav. 2018;187:20-23.
- Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes. Diabetes Obes Metab. 2007;9(6):799-812.
